HCWB
HCW Biologics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.87
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
Market Cap
$5.27M
MomentumView details →
1D Return
+0.00%
YTD Return
−50.69%
RSI (14)
44.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
Market Cap
$5.27M
RSI (14)
44.9
MomentumView details →
1D Return
+0.00%
YTD Return
−50.69%
SummaryUpdated Jun 1, 2026
HCW Biologics Inc. (NASDAQ:HCWB) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Miramar, Florida. The company went public in July 2021 and focuses on developing novel immunotherapies targeting chronic, low-grade inflammation and age-related diseases. HCW Biologics operates in the highly specialized field of cancer immunotherapy and autoimmune disease treatment, with a pipeline of experimental drugs in various stages of development from preclinical research to Phase II clinical trials.
Similar companies
Latest newsMore news →
HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata.2d agoHCW Biologics Inc. priced a $1.6 million private placement offering of units consisting of common stock or pre-funded warrants and common stock purchase warrants to a group of investors including officers, directors and an existing stockholder.37d agoHCW Biologics announced positive preliminary human data readout for its Phase 1 clinical trial of HCW9302 in alopecia areata.81d ago